Phospho-BCL2 (Ser87) Antibody

What is Phospho-BCL2 (Ser87) Antibody and what does it specifically detect?

Phospho-BCL2 (Ser87) Antibody is a specialized antibody that recognizes BCL-2 protein only when phosphorylated at the Serine 87 residue. The antibody detects endogenous levels of BCL-2 specifically when this particular serine is phosphorylated, without cross-reactivity to unphosphorylated BCL-2 or BCL-2 phosphorylated at other sites. This specificity makes it valuable for studying phosphorylation-dependent regulation of BCL-2 function. Most commercially available antibodies are rabbit polyclonal antibodies, though mouse monoclonal versions also exist, with molecular weight detection around 26-28kDa .

What methodological approaches should be used to validate Phospho-BCL2 (Ser87) Antibody specificity?

To validate antibody specificity, researchers should implement multiple complementary approaches:

• Phosphatase treatment: Treat cell lysates with lambda phosphatase prior to Western blotting. The signal should disappear if the antibody is truly phospho-specific.

• Phosphorylation-deficient mutants: Compare wild-type BCL-2 with a Ser87Ala mutant expression system. The mutant should show minimal to no detection.

• Induction experiments: Compare untreated cells with those treated with known inducers of Ser87 phosphorylation (e.g., paclitaxel at 1μM for 16 hours). The signal should increase in treated samples .

• Kinase inhibitor controls: Treat cells with specific inhibitors like SB203580 (p38MAPK inhibitor) or PD98059 (MEK/ERK inhibitor). If these pathways mediate Ser87 phosphorylation, the signal should decrease proportionally .

What are the recommended applications and experimental conditions for using this antibody?

Phospho-BCL2 (Ser87) Antibody has been validated for multiple applications:

For optimal results, sample preparation should include phosphatase inhibitors (50mM NaF, 2mM sodium orthovanadate, 5mM EDTA, 5mM EGTA) to preserve phosphorylation status . Jurkat cells treated with 1μM paclitaxel for 16 hours serve as an effective positive control for most applications .

What is the functional significance of BCL-2 phosphorylation at Ser87?

The functional significance of BCL-2 phosphorylation at Ser87 is complex and context-dependent:

• Protein stability regulation: Dephosphorylation of Ser87 appears to be a critical signal for ubiquitin-dependent degradation of BCL-2. Ser-to-Ala substitution at this position results in approximately 50% degradation of the protein .

• Apoptotic regulation: Phosphorylation status at Ser87, especially in combination with phosphorylation at other sites (Thr69, Ser70), can significantly modulate BCL-2's anti-apoptotic function. The precise effect depends on whether single-site or multi-site phosphorylation occurs .

• Protein-protein interaction modulation: Surface plasmon resonance studies have shown that phosphorylation alters BCL-2's binding affinity for pro-apoptotic proteins like Bim and Bak, potentially through conformational changes in the flexible loop domain .

• Cell cycle dependency: BCL-2 is naturally phosphorylated at Ser87 during the G2/M phase of the cell cycle, potentially as a mechanism to temporarily modulate apoptotic sensitivity during mitosis .

Which kinases and phosphatases regulate BCL-2 phosphorylation at Ser87?

Several kinases have been identified that can phosphorylate BCL-2 at Ser87:

• JNK1 (c-Jun N-terminal kinase 1): Activated during stress responses and at G2/M phase of the cell cycle .

• p38MAPK: Particularly activated during viral infections like Influenza A, which increases Ser87 phosphorylation by 71% in infected cells .

• ERK1/2 (Extracellular signal-regulated kinases): Activated by growth factors and contributes to Ser87 phosphorylation in multiple cell types .

The primary phosphatase counterbalancing this phosphorylation is protein phosphatase 2A (PP2A), which can dephosphorylate BCL-2 at Ser87, potentially targeting it for degradation. Inhibition of PP2A with specific inhibitors like okadaic acid can increase Ser87 phosphorylation levels .

How does phosphorylation at Ser87 compare to other BCL-2 phosphorylation sites?

Phosphorylation at different BCL-2 sites has distinct functional implications:

Research indicates that while Ser70 phosphorylation is generally associated with enhanced anti-apoptotic function, Ser87 phosphorylation may have more complex effects depending on cellular context and whether other sites are simultaneously phosphorylated .

What experimental conditions induce or reduce BCL-2 phosphorylation at Ser87?

Several experimental conditions modulate BCL-2 phosphorylation at Ser87:

Induction conditions:

• Paclitaxel treatment: 1μM for 16-24 hours induces multi-site phosphorylation including Ser87

• Viral infections: Influenza A virus activates p38MAPK, leading to increased Ser87 phosphorylation

• Bile acids: Glycochenodeoxycholate (GCDA) at 100μM stimulates ERK1/2 activation and subsequent BCL-2 phosphorylation

• Cell cycle synchronization: G2/M phase arrest shows increased Ser87 phosphorylation

Reduction conditions:

• p38MAPK inhibitor SB203580: Reduces virus-induced Ser87 phosphorylation by approximately 71%

• MEK/ERK inhibitor PD98059: Blocks GCDA-stimulated phosphorylation in a dose-dependent manner

• TNF-α treatment: Can induce dephosphorylation of Ser87 in certain cell types

• Oxidative stress: Reduces MAP kinase activity, leading to Ser87 dephosphorylation

How can I design experiments to study the dynamics of BCL-2 phosphorylation at Ser87?

To study phosphorylation dynamics:

• Time-course analysis: Treat cells with phosphorylation inducers and collect samples at multiple timepoints (5, 15, 30 minutes, 1, 2, 4, 8, 24 hours) to capture both rapid and delayed responses.

• Pulse-chase studies: Induce phosphorylation, then remove the stimulus (e.g., by washing out the drug or adding specific inhibitors) and monitor dephosphorylation rates.

• Cellular fractionation: Separate mitochondrial, cytosolic, and nuclear fractions to determine if Ser87 phosphorylation affects BCL-2 subcellular localization.

• Combine with apoptosis assays: Correlate Ser87 phosphorylation levels with measures of apoptosis (caspase activation, PARP cleavage, annexin V staining) to establish functional relationships.

• Generate phosphomimetic mutants: Express S87E (phosphomimetic) or S87A (phosphodeficient) BCL-2 mutants to study the functional consequences of constitutive phosphorylation or dephosphorylation .

How is BCL-2 phosphorylation at Ser87 implicated in cancer drug responses?

BCL-2 phosphorylation at Ser87 has important implications for cancer therapy:

• Chemoresistance: In liver cancer cells, bile acid-induced phosphorylation of BCL-2 contributes to chemoresistance through the ERK1/2 pathway. Inhibiting this phosphorylation can potentially sensitize resistant cells to therapeutic agents .

• Microtubule inhibitors: Paclitaxel and other microtubule-targeting drugs induce multi-site phosphorylation of BCL-2, including at Ser87, which may contribute to their apoptotic effects. This phosphorylation is particularly prominent in breast cancer cells like MDA-MB-231 .

• Mathematical modeling: Systems analysis of phosphorylation-regulated BCL-2 interactions has revealed that the effect of phosphorylation on anti-apoptotic function depends on both the extent of phosphorylation and the specific BH3-only proteins involved. For example, with Bmf stress, BCL-2 phosphorylation switches from diminishing to enhancing anti-apoptotic ability with increased phosphorylation levels .

• Kinase inhibitor combinations: Combining traditional chemotherapeutics with inhibitors targeting kinases responsible for Ser87 phosphorylation may represent a strategy for overcoming drug resistance in cancers with high BCL-2 expression .

How can I distinguish between single-site and multi-site phosphorylation of BCL-2?

To differentiate single-site from multi-site phosphorylation:

• Mobility shift analysis: Multi-site phosphorylation produces a more pronounced mobility shift (to approximately 29kDa) in SDS-PAGE compared to single-site phosphorylation (around 26-28kDa) .

• Site-specific phospho-antibodies: Compare signals using antibodies against individual phosphorylation sites (pSer87, pSer70, pThr69). Different ratios indicate different phosphorylation patterns.

• Two-dimensional peptide mapping: This technique can resolve distinct phosphopeptides corresponding to different phosphorylation sites, providing a comprehensive picture of the phosphorylation status .

• Phosphomutant analysis: Generate single, double, and triple phospho-mutants (S→A or S→E substitutions) as reference controls.

• Mass spectrometry: Provides the most definitive analysis of phosphorylation sites, allowing precise identification and quantification of multiple phosphorylation events .

What is the relationship between BCL-2 phosphorylation at Ser87 and its proteasomal degradation?

The relationship between Ser87 phosphorylation and proteasomal degradation is intricate:

• Dephosphorylation signal: Research has demonstrated that dephosphorylation of Ser87 serves as a critical signal for BCL-2's ubiquitin-dependent degradation .

• Phosphomimetic protection: When Ser87 is replaced with a phosphate-mimetic aspartic acid residue (S87D), TNF-α-triggered BCL-2 degradation is profoundly reduced both in vivo and in vitro, confirming the protective role of phosphorylation .

• Oxidative stress connection: Oxidative stress mediates TNF-α-stimulated proteolytic degradation of BCL-2 by inactivating MAP kinases, which leads to dephosphorylation of Ser87 and subsequent degradation .

• Subcellular specificity: BCL-2 degradation may occur preferentially at specific subcellular locations, such as the mitochondria and endoplasmic reticulum, where different pools of kinases and phosphatases regulate Ser87 phosphorylation status .

How do cell cycle dynamics influence BCL-2 phosphorylation at Ser87?

BCL-2 phosphorylation at Ser87 is tightly linked to cell cycle progression:

• G2/M enrichment: Studies using centrifugal elutriation to separate cells in different cell cycle phases have demonstrated that BCL-2 is normally phosphorylated at Ser87 during the G2/M phase .

• Kinase activation: ASK1 and JNK1 are normally activated at G2/M phase, leading to increased BCL-2 phosphorylation at multiple sites including Ser87 .

• Apoptotic sensitivity: G2/M-phase cells show increased susceptibility to death signals, and phosphorylation of BCL-2 appears to be responsible. When Ser87 is mutated to alanine, resistance to apoptosis is partially restored .

• Microtubule inhibitor connection: Drugs that arrest cells at G2/M, such as paclitaxel, induce hyperphosphorylation of BCL-2 at multiple sites including Ser87, potentially explaining their effectiveness against BCL-2-expressing tumors .

How can sophisticated modeling approaches enhance our understanding of BCL-2 phosphorylation dynamics?

Mathematical and computational approaches provide valuable insights into complex phosphorylation dynamics:

• Ordinary differential equation (ODE) models: These can quantitatively describe the phosphorylation/dephosphorylation cycle and predict how changes in kinase/phosphatase activity affect BCL-2 function .

• Systems biology approaches: Combining experimental data with computational modeling has revealed that the effect of BCL-2 phosphorylation depends on both the extent of modification and the specific binding partners involved .

• Binding kinetics integration: Surface plasmon resonance data on how phosphorylation affects BCL-2 binding to partners like Bim and Bak can be incorporated into models to predict functional outcomes .

• Drug response prediction: Models integrating phosphorylation status can accurately predict the effects of anti-tumor drugs that involve the BCL-2 family pathway, as demonstrated with ABT-199 and etoposide .

• In silico mutation analysis: Computational prediction of how mutations at Ser87 and other phosphorylation sites affect protein stability, conformation, and interaction networks can guide experimental design .

What are common technical challenges when using Phospho-BCL2 (Ser87) Antibody?

Researchers frequently encounter these challenges:

• Low signal intensity: Phosphorylation is often transient and substoichiometric. Enrich phosphoproteins or use phosphatase inhibitors (50mM NaF, 2mM sodium orthovanadate) during sample preparation .

• High background: Use 5% BSA instead of milk for blocking Western blots, as milk contains phosphoproteins that may interfere with detection. Optimize antibody concentration (typically 1:500-1:2000) .

• Inconsistent results between experiments: Standardize cell culture conditions, as phosphorylation status can be affected by cell density, serum levels, and passage number.

• Conflicting literature reports: The functional consequence of Ser87 phosphorylation appears context-dependent. Carefully consider cell type, stimulus, and whether other sites are simultaneously phosphorylated when interpreting results .

• Antibody cross-reactivity: Validate antibody specificity using phospho-deficient mutants and phosphatase treatment to ensure signal specificity .

How can I optimize sample preparation to preserve BCL-2 phosphorylation at Ser87?

To maintain phosphorylation integrity:

• Rapid processing: Minimize the time between cell harvesting and protein extraction to prevent dephosphorylation by endogenous phosphatases.

• Phosphatase inhibitors: Include a comprehensive mixture (50mM NaF, 2mM sodium orthovanadate, 5mM EDTA, 5mM EGTA) in all buffers used during sample preparation .

• Cold temperature: Maintain samples at 4°C throughout processing to reduce phosphatase activity.

• Lysis buffer optimization: Use buffers containing 1% NP-40 or Triton X-100, which effectively solubilize membrane-associated BCL-2 while preserving phosphorylation.

• Avoid freeze-thaw cycles: Phosphorylation status can be compromised by repeated freezing and thawing. Aliquot samples after preparation .

• Denaturing conditions: Add SDS sample buffer directly to cells for immediate denaturation when possible, which rapidly inactivates phosphatases.